---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-115406"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:07:04.078237+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q3 DEXTENZA revenue flat at $11.9M; net loss $24.2M; revises 2022 guidance to $48-52M

## Summary
- DEXTENZA net product revenue $11.9M in Q3 2022, flat YoY and down ~2% sequentially; 2022 guidance revised to $48-52M (10-20% growth).
- Net loss $24.2M ($0.31/share) vs net income $2.7M ($0.03/share) in Q3 2021; includes $1.1M non-cash derivative liability adjustment.
- OTX-TKI Phase 1 wet AMD interim: 80% rescue-free at 6 months, 73% at 7 months; Phase 2/3 planned for Q3 2023.
- Phase 1 trial for diabetic retinopathy expected to start Q1 2023; OTX-TIC Phase 2 enrollment ongoing, topline data Q4 2023.
- Cash and equivalents $121.0M as of Sep 30, 2022; sufficient to fund operations through 2023.

## SEC filing metadata
- accession: 0001104659-22-115406
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465922115406/0001104659-22-115406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465922115406/tm2229787d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-115406
- JSON: https://secwatch.observer/filing/0001104659-22-115406.json
- Plain text: https://secwatch.observer/filing/0001104659-22-115406.txt

## Key facts
- Earnings Releases
  OCULAR THERAPEUTIX, INC updated its the quarter ended September 30, 2022 guidance (reaffirmed).
  - Period: the quarter ended September 30, 2022
  - Guidance: reaffirmed
  - Result: reported results
  source text: On November 7, 2022, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465922115406/0001104659-22-115406-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.